- Home
- NFBK vs ARCT Comparison
NFBK vs ARCT Comparison
Compare NFBK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- ARCT
- Stock Information
- Founded
- NFBK 1887
- ARCT 2013
- Country
- NFBK United States
- ARCT United States
- Employees
- NFBK N/A
- ARCT N/A
- Industry
- NFBK Major Banks
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- ARCT Health Care
- Exchange
- NFBK Nasdaq
- ARCT Nasdaq
- Market Cap
- NFBK 406.5M
- ARCT 298.3M
- IPO Year
- NFBK 2007
- ARCT N/A
- Fundamental
- Price
- NFBK $11.41
- ARCT $13.63
- Analyst Decision
- NFBK Buy
- ARCT Strong Buy
- Analyst Count
- NFBK 2
- ARCT 8
- Target Price
- NFBK $13.00
- ARCT $52.83
- AVG Volume (30 Days)
- NFBK 197.4K
- ARCT 473.3K
- Earning Date
- NFBK 07-23-2025
- ARCT 08-04-2025
- Dividend Yield
- NFBK 4.53%
- ARCT N/A
- EPS Growth
- NFBK 1.58
- ARCT N/A
- EPS
- NFBK 0.76
- ARCT N/A
- Revenue
- NFBK $128,407,000.00
- ARCT $143,680,000.00
- Revenue This Year
- NFBK $8.33
- ARCT N/A
- Revenue Next Year
- NFBK $15.77
- ARCT $34.08
- P/E Ratio
- NFBK $15.09
- ARCT N/A
- Revenue Growth
- NFBK N/A
- ARCT 15.38
- 52 Week Low
- NFBK $9.40
- ARCT $8.04
- 52 Week High
- NFBK $14.39
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- NFBK 46.12
- ARCT 54.30
- Support Level
- NFBK $11.18
- ARCT $12.75
- Resistance Level
- NFBK $12.50
- ARCT $15.20
- Average True Range (ATR)
- NFBK 0.33
- ARCT 0.92
- MACD
- NFBK -0.07
- ARCT -0.07
- Stochastic Oscillator
- NFBK 27.26
- ARCT 43.92
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.